TY - JOUR
T1 - Recommendations for defining treatment outcomes in major psychiatric disorders using real-world data
AU - Koch, Elise
AU - Smart, Sophie
AU - Einarsson, Guðmundur
AU - Kämpe, Anders
AU - Jonsson, Lina
AU - Alver, Maris
AU - Iveson, Matthew
AU - Göteson, Andreas
AU - Pardiñas, Antonio F.
AU - Sønderby, Ida E.
AU - O'Connell, Kevin S.
AU - Li, Qingqin
AU - Lu, Yi
AU - Stefánsson, Hreinn
AU - Stefánsson, Kári
AU - Whalley, Heather
AU - Landén, Mikael
AU - O'Donovan, Michael C.
AU - Smerud, Knut
AU - Dawson, Gerard R.
AU - Werge, Thomas
AU - Buil, Alfonso
AU - Reif, Andreas
AU - Milani, Lili
AU - Molden, Espen
AU - Fabbri, Chiara
AU - Serretti, Alessandro
AU - Walters, James
AU - Lewis, Cathryn M.
AU - Andreassen, Ole A.
N1 - Publisher Copyright:
© 2025 Elsevier Ltd
PY - 2025
Y1 - 2025
N2 - Although information from real-world data can be used to identify factors that aid treatment choice, there are no guidelines for the use of such data. The aim of this Review is to summarise and evaluate definitions of treatment outcomes for antidepressants, antipsychotics, and mood stabilisers when using real-world data, and to suggest standards for the field. Given that no standards for the use of these data in estimating treatment outcomes exist, variability is high for treatment outcome definitions. We make recommendations for different scenarios of available data and highlight the importance of using other sources of information to validate proxy measures such as continued treatment, switching between medications, or polypharmacy of psychotropic medications. Well defined and validated treatment outcome measures that incorporate real-world data could facilitate the development of precision psychiatry approaches and support regulatory decision making regarding psychopharmacological agents.
AB - Although information from real-world data can be used to identify factors that aid treatment choice, there are no guidelines for the use of such data. The aim of this Review is to summarise and evaluate definitions of treatment outcomes for antidepressants, antipsychotics, and mood stabilisers when using real-world data, and to suggest standards for the field. Given that no standards for the use of these data in estimating treatment outcomes exist, variability is high for treatment outcome definitions. We make recommendations for different scenarios of available data and highlight the importance of using other sources of information to validate proxy measures such as continued treatment, switching between medications, or polypharmacy of psychotropic medications. Well defined and validated treatment outcome measures that incorporate real-world data could facilitate the development of precision psychiatry approaches and support regulatory decision making regarding psychopharmacological agents.
U2 - 10.1016/S2215-0366(25)00061-6
DO - 10.1016/S2215-0366(25)00061-6
M3 - Review
C2 - 40222385
AN - SCOPUS:105002751797
SN - 2215-0366
VL - 12
SP - 457
EP - 468
JO - The Lancet Psychiatry
JF - The Lancet Psychiatry
IS - 6
ER -